Julen Fernández-Plana

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype

David Páez, M. Tobeña, Julen Fernández-Plana et al. · British Journal of Cancer · 2018 · 40 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti–Epidermal Growth Factor Receptor Therapy

Joan Maurel, Vicente Alonso, P. Escudero et al. · JCO Precision Oncology · 2019 · 27 citations

Medicine, Molecular Genetics, Oncology +17

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRASmetastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

Julen Fernández-Plana, Carles Pericay, Guillermo Quintero et al. · BMC Cancer · 2014 · 23 citations · Full text

Medicine, Oncology, Pharmacology +14

Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting

Margarita Romeo, Marta Gil-Martín, Lydia Gaba et al. · Cancers · 2022 · 22 citations · Full text

Medicine, Gynecology, Oncology +16

An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study

Caiming Xu, Alessandro Mannucci, F. Espósito et al. · Clinical Cancer Research · 2025 · 19 citations · Full text

Medicine, Oncology, Pharmacology +17